Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cross-neutralization of sIPV in Infants
NCT04618783Phase 2Completed
- Sponsor
- Sinovac Biotech Ltd.
- Start
- Jul 2019
- Primary completion
- Dec 2019
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of Sabin strain inactivated poliovirus vaccine in poliomyelitis (5 arms), sponsored by Sinovac Biotech Ltd. Primary endpoint: Immunity index of seroconversion rate. Started Jul 2019; status: completed.
02
Drugs
Sabin strain inactivated poliovirus vaccine
03
Conditions
poliomyelitis
Beyond the preview
Go deeper on NCT04618783.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04618783.